IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
ImmunoPrecise Antibodies (NASDAQ: IPA) has announced a strategic collaboration with RIBOPRO to enhance therapeutic antibody discovery by combining RIBOPRO's mRNA and lipid nanoparticle (LNP) technologies with IPA's AI-powered discovery capabilities.
The partnership aims to overcome challenges in antigen expression during antibody discovery by utilizing RIBOPRO's expertise in mRNA sequence optimization and LNP-based delivery alongside IPA's advanced B-cell screening, single-cell analysis, and deep-learning AI workflows.
This integration of mRNA immunization into IPA's discovery pipeline is expected to improve antigen presentation and immune responses, potentially accelerating the development of novel therapeutics.
ImmunoPrecise Antibodies (NASDAQ: IPA) ha annunciato una collaborazione strategica con RIBOPRO per migliorare la scoperta di anticorpi terapeutici, combinando le tecnologie mRNA e nanoparticelle lipidiche (LNP) di RIBOPRO con le capacità di scoperta alimentate dall'IA di IPA.
Il partenariato mira a superare le sfide nell'espressione degli antigeni durante la scoperta degli anticorpi, sfruttando l'expertise di RIBOPRO nell'ottimizzazione delle sequenze mRNA e nella somministrazione basata su LNP, insieme allo screening avanzato delle cellule B, all'analisi delle singole cellule e ai flussi di lavoro di deep learning di IPA.
Questa integrazione dell'immunizzazione mRNA nel pipeline di scoperta di IPA dovrebbe migliorare la presentazione degli antigeni e le risposte immunitarie, accelerando potenzialmente lo sviluppo di nuovi terapeutici.
ImmunoPrecise Antibodies (NASDAQ: IPA) ha anunciado una colaboración estratégica con RIBOPRO para mejorar el descubrimiento de anticuerpos terapéuticos al combinar las tecnologías de ARNm y nanopartículas lipídicas (LNP) de RIBOPRO con las capacidades de descubrimiento impulsadas por IA de IPA.
La asociación tiene como objetivo superar los desafíos en la expresión de antígenos durante el descubrimiento de anticuerpos, utilizando la experiencia de RIBOPRO en la optimización de secuencias de ARNm y la entrega basada en LNP, junto con el avanzado cribado de células B, el análisis de células individuales y los flujos de trabajo de IA de aprendizaje profundo de IPA.
Se espera que esta integración de la inmunización con ARNm en el pipeline de descubrimiento de IPA mejore la presentación de antígenos y las respuestas inmunitarias, acelerando potencialmente el desarrollo de nuevos terapéuticos.
ImmunoPrecise Antibodies (NASDAQ: IPA)는 RIBOPRO와 전략적 협력을 발표하여 RIBOPRO의 mRNA 및 지질 나노입자(LNP) 기술과 IPA의 AI 기반 발견 능력을 결합하여 치료용 항체 발견을 향상시키고자 합니다.
이번 파트너십은 항체 발견 과정에서 항원 발현의 문제를 극복하기 위해 RIBOPRO의 mRNA 서열 최적화 및 LNP 기반 전달 전문성과 IPA의 고급 B세포 스크리닝, 단일 세포 분석 및 심층 학습 AI 워크플로우를 활용하는 것을 목표로 합니다.
mRNA 면역화를 IPA의 발견 파이프라인에 통합함으로써 항원 제시 및 면역 반응이 개선되어 새로운 치료제 개발이 가속화될 것으로 기대됩니다.
ImmunoPrecise Antibodies (NASDAQ: IPA) a annoncé une collaboration stratégique avec RIBOPRO pour améliorer la découverte d'anticorps thérapeutiques en combinant les technologies d'ARNm et de nanoparticules lipidiques (LNP) de RIBOPRO avec les capacités de découverte alimentées par l'IA d'IPA.
Ce partenariat vise à surmonter les défis d'expression des antigènes lors de la découverte d'anticorps en utilisant l'expertise de RIBOPRO dans l'optimisation des séquences d'ARNm et la livraison basée sur LNP, en plus du criblage avancé des cellules B, de l'analyse des cellules uniques et des flux de travail d'IA de deep learning d'IPA.
L'intégration de l'immunisation par ARNm dans le pipeline de découverte d'IPA devrait améliorer la présentation des antigènes et les réponses immunitaires, ce qui pourrait potentiellement accélérer le développement de nouveaux thérapeutiques.
ImmunoPrecise Antibodies (NASDAQ: IPA) hat eine strategische Zusammenarbeit mit RIBOPRO angekündigt, um die Entdeckung therapeutischer Antikörper zu verbessern, indem die mRNA- und Lipid-Nanopartikel (LNP)-Technologien von RIBOPRO mit den KI-gestützten Entdeckungsfähigkeiten von IPA kombiniert werden.
Das Partnerschaftsziel besteht darin, Herausforderungen bei der Antigenexpression während der Antikörperentdeckung zu überwinden, indem die Expertise von RIBOPRO in der Optimierung von mRNA-Sequenzen und LNP-basierter Lieferung zusammen mit dem fortschrittlichen B-Zell-Screening, der Einzelzellanalyse und den Deep-Learning-KI-Workflows von IPA genutzt wird.
Diese Integration der mRNA-Immunisierung in den Entdeckungsprozess von IPA wird voraussichtlich die Antigenpräsentation und die Immunantworten verbessern, was potenziell die Entwicklung neuer Therapeutika beschleunigen könnte.
- Strategic integration of advanced mRNA/LNP technology enhances IPA's antibody discovery capabilities
- Partnership potentially accelerates therapeutic development timeline
- Expansion of IPA's technological toolbox for antibody discovery
- None.
Insights
ImmunoPrecise Antibodies' partnership with RIBOPRO represents a strategic technology integration that could strengthen IPA's competitive position in the specialized antibody discovery market. For context, IPA is an extremely small player with its $18.6M market capitalization, operating in a field dominated by much larger companies with substantial R&D resources.
This collaboration strategically combines two transformative technologies that have gained significant validation: mRNA delivery systems (popularized through COVID-19 vaccines) and AI-driven drug discovery. The technical advantage appears substantial - traditional antibody discovery often struggles with complex antigens that don't express properly during immunization, potentially limiting the quality and diversity of antibodies generated. RIBOPRO's mRNA and LNP technologies could enable more precise antigen presentation, potentially unlocking antibodies against previously challenging targets.
From an investment perspective, this partnership lacks concrete financial terms or commercial milestones, making immediate revenue impact impossible to quantify. However, for micro-cap biotechs like IPA, platform technology enhancements can significantly impact valuation through:
- Improved success rates in discovery partnerships
- Enhanced competitive positioning for pharmaceutical collaborations
- Potential expansion of addressable targets
- Increased probability of generating valuable intellectual property
The antibody therapeutics market exceeds
The collaboration leverages RIBOPRO’s expertise in mRNA sequence optimization and LNP-based delivery with IPA’s advanced B-cell screening, single-cell analysis, and deep-learning AI-driven discovery workflows. Together, the two companies aim to accelerate and enhance the development of novel therapeutics by improving antigen presentation and immune responses, a critical step in antibody discovery.
Transforming Antibody Discovery with mRNA Technology
The success of generating therapeutic lead antibodies towards complex antigens using traditional immunization-based discovery platforms may be hampered by challenges associated with the proper expression of these antigens. By leveraging RIBOPRO’s proprietary mRNA and LNP technologies, this partnership enables precise, efficient antigen expression, thereby facilitating potentially more effective immune responses and possibly accelerating the path to discovering novel antibody therapeutics.
“Partnering with ImmunoPrecise Antibodies enables us to push the boundaries of mRNA-based immunization for therapeutic antibody discovery,” said Sander van Asbeck, CEO of RIBOPRO. “By integrating our expertise in mRNA design and nanoparticle delivery with IPA’s cutting-edge antibody discovery and engineering capabilities, we can address longstanding challenges in antigen expression, bringing forth new possibilities for precision therapeutics.”
Driving Innovation in AI-Powered Antibody Discovery
IPA’s approach combines advanced AI-driven analytics with highly specialized wet-lab methodologies to design and optimize antibodies with the highest clinical relevance. The integration of mRNA immunization into IPA’s workflow is expected to further enhance the precision and efficiency of their antibody discovery pipeline.
“We are enthusiastic to expand our toolbox for the discovery of novel therapeutic antibodies with a state-of-the-art mRNA immunization platform in this alliance,” said Dr. Ilse Roodink, CSO of ImmunoPrecise Antibodies. “Combining RIBOPRO’s and IPA’s unique expertise further strengthens our commitment to be at the forefront of solving complex challenges with innovative and high-quality solutions.”
About RIBOPRO
RIBOPRO is a
For more information, visit www.ribopro.eu
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutic research and technology company specializing in AI-driven antibody discovery and development. Through its subsidiaries—including Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (
For more information, visit www.ipatherapeutics.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable
Although the Company believes it has a reasonable basis for these forward-looking statements, they are based on current expectations, assumptions, and projections about future events that involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors largely beyond the Company’s control, including risks related to scientific and technological developments, regulatory approvals, industry competition, and broader market conditions.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information on risks and uncertainties can be found in the Company’s Annual Report on Form 20-F, as amended, for the year ended April 30, 2024, (available on the Company’s SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should any of these risks materialize, actual results could vary significantly. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect the Company’s expectations only as of the date of this release. The Company assumes no obligation to update or revise these statements, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226852583/en/
Media Contact:
Silvy van Tuijl
Chief of Staff, RIBOPRO
info@ribopro.eu
+31 85 060 67 62
Investor Contact: investors@ipatherapeutics.com
Source: ImmunoPrecise Antibodies Ltd.
FAQ
What is the strategic partnership between ImmunoPrecise Antibodies (IPA) and RIBOPRO focused on?
How will RIBOPRO's technology enhance IPA's antibody discovery process?
What specific technologies does IPA bring to the RIBOPRO collaboration?
What problem does the IPA-RIBOPRO collaboration aim to solve in antibody discovery?
